Lent score validation on patients with malignant pleural effusion

Ioannis Psallidas (Oxford, United Kingdom), Ioannis Psallidas, Nikolaos Kannelakis, Ahmed Yousuf, John Corcoran, Rob Hallifax, John Wrightson, Rachel Mercer, Ambika Talwar, Najib Rahman

Source: International Congress 2016 – Malignant pleural disease: diagnosis and management
Session: Malignant pleural disease: diagnosis and management
Session type: Poster Discussion
Number: 3385
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Ioannis Psallidas (Oxford, United Kingdom), Ioannis Psallidas, Nikolaos Kannelakis, Ahmed Yousuf, John Corcoran, Rob Hallifax, John Wrightson, Rachel Mercer, Ambika Talwar, Najib Rahman. Lent score validation on patients with malignant pleural effusion. Eur Respir J 2016; 48: Suppl. 60, 3385

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Predictive parameters of survival in malignant pleural effusion
Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Year: 2015


Solitary fibrous tumour of the pleural: Two malignant cases
Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors
Year: 2015


Malignant pleural effusion (MPE) as debut of cancer
Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Year: 2015


What outcome after pleurodesis in malignant pleural effusion in lung cancer?
Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors
Year: 2015


Pleural ultrasonic elastography in the diagnosis of malignant pleural effusion
Source: International Congress 2016 – Malignant pleural disease: diagnosis and management
Year: 2016

Malignant pleural effusion as the initial manifestation of gynecological malignancies
Source: International Congress 2016 – Malignant pleural disease: diagnosis and management
Year: 2016


CT scanner for the pleural staging of pleural cancer: How accurate is this?
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014

Pleural mesothelioma with solitary simultaneous subcutaneous tissue metastasis of the abdominal wall at diagnosis - First clinical documentation
Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Year: 2013


Hemorrhagic malignant pleural effusion: Diagnosis, survival rate, and response to talc pleurodesis
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014


Ideal volume sampling in the diagnosis of malignant pleural effusions. Just how much is really enough?
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013

Blood-staining of pleural fluid is an inaccurate predictor of pleural malignancy
Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Year: 2015


Role of Dr-70 immunoassay in suspected malignant pleural effusion
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013


An examination of the factors for successful pleurodesis against malignant pleural effusion (MPE)
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016


Detection of EpCAM-positive microparticles in pleural fluid: A new approach for the diagnosis of the tumoral origin of pleural effusions
Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management
Year: 2015



Risk of occult pleural infection in patients with malignant effusions
Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases
Year: 2013


Survival of non small cell lung carcinoma patients with malignant pleural effusions
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014


The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion
Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions
Year: 2013



LATE-BREAKING ABSTRACT: A proteomic study of benign and malignant pleural effusions
Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Year: 2015

Talc pleurodesis for malignant pleural effusion - effect on survival: Case-control follow-up study
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014


Comparison analysis of malignant and tuberculous pleural fluid using proteomic method
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016